necvax-neo1
Vaccineexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 5, 2022 (NCT05354323)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Tumor antigensImmunity, active
immunity, active - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06631079 | Phase 1/Phase 2 (Phase 2) | Oct 7, 2024 | NEC |
| NCT05354323 | Phase 1 | May 5, 2022 | NEC OncoImmunity AS |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| NEC | For profit | 1 | 1 | 1 | 2024 |
| NEC OncoImmunity AS | For profit | 1 | 1 | 1 | 2022 |
2 organizations
Page 1 / 1